Floatz logo

Epirubicin

Hormone-Resistant Prostate Cancer

University of Wisconsin, MadisonPhase 2Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Hormone-Resistant Prostate Cancer cohort.

Asset / SponsorPhaseRating
Cediranib
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2BB
Docetaxel
Seattle Institute for Biomedical and Clinical Research
Phase 3BB
Enzalutamide
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 3BB
Cyclophosphamide
University of Wisconsin, Madison
Phase 2BB
Casodex
Mayo Clinic
Phase 2B

View all 26 →

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →